WisdomTree U.S. High Yield Corporate Bond Fund (BATS: QHY)

Latest news for WisdomTree U.S. High Yield Corporate Bond Fund (BATS:QHY)

Under normal circumstances, at least 80% of the funds total assets will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is designed to capture the performance of selected issuers in the U.S. non-investment-grade corporate bond market that are deemed to have favorable fundamental and income characteristics. The fund is non-diversified.

State Street Navigator Securities Lending Government Money Market Portfolio

WisdomTree US High Yield Corporate Bond Fund

WisdomTree U.S. High Yield Corporate Bond Fund

QHY Group

QHY GROUP by QHY Group

WIIM

VRME

VerifyMe shares are trading higher after the company announced its board approved a share repurchase plan extension to December 31, 2025.

Trading Ideas

ZENA

ZenaTech Shares Halted On Circuit Breaker To The Downside, Stock Now Up 63.5%

Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) faced significant service disruptions on Monday with close to 5,400 people reporting issues with Microsoft 365 on the <a href="https://downdetector.com/status/microsoft-365/" target="_blank" rel="noreferrer noopener">Down Detector</a> around noon EST. 
Around 84% of reports stemmed from Outlook, 10% from Exchange, and 6% from Sharepoint.
Close to 8,500 users reported issues with Microsoft Outlook as per <a target="_blank" href="https://downdetector.com/status/outlook/" rel="noreferrer noopener">Down Detector</a>, with 67% of problems corresponding to the website, 22% with the app, and 11% with login issues.
Also Read: <a href="https://www.benzinga.com/24/11/42143717/best-buys-growth-hinges-on-computing-and-services-as-q3-approaches-analyst" target="_blank" rel="noreferrer noopener">Best Buy&#8217;s Growth Hinges On Computing And Services As Q3 Approaches: Analyst</a>
Over 300 users reported issues associated with Microsoft Teams on the <a target="_blank" href="https://downdetector.com/status/teams/" rel="noreferrer noopener">Down Detector</a>, with 61% of the problems related to the server connection, 26% to the website, and 13% to the website.
Microsoft <a href="https://x.com/MSFT365Status/status/1860973220662280356" target="_blank" rel="noreferrer noopener">tweeted</a> at 4:06 am ET that users faced issues with Exchange Online and Microsoft Teams calendars.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We&#39;re investigating an issue impacting users attempting to access Exchange Online or functionality within Microsoft Teams calendar. For more information, please refer to MO941162 in the admin center.
&mdash; Microsoft 365 Status (@MSFT365Status) <a href="https://twitter.com/MSFT365Status/status/1860973220662280356?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
At 9:03 am ET, the company <a target="_blank" href="https://x.com/MSFT365Status/status/1861047970143019048" rel="noreferrer noopener">tweeted</a> that it had deployed a fix progressing through the affected environment. At the same time, it began a manual restart on a subset of affected machines.
At 12:25 pm ET, the company <a target="_blank" href="https://x.com/MSFT365Status/status/1861098870547120306" rel="noreferrer noopener">tweeted</a> that targeted restarts were progressing slower than anticipated for most affected users.
At 5:59 pm ET Tuesday, it <a target="_blank" href="https://x.com/MSFT365Status/status/1861182988022624262" rel="noreferrer noopener">tweeted</a> incremental recovery for some users and focused on additional workstreams to resolve all customers&#8217; issues.
Microsoft&#8217;s <a href="https://admin.microsoft.com/servicestatus" target="_blank" rel="noreferrer noopener">current status</a> says users may be unable to access or use some of Microsoft 365&#8217;s services and features.
OpenAI ChatGPT services also experienced <a href="https://status.openai.com/">disruption on Monday</a>. Users flagged elevated errors on ChatGPT and API from 1:20 pm ET. ChatGPT recovered by 2:55 pm ET, and API performance was recovered for most customers by 4:30 pm ET. The number of issues reported crossed 2,100 on Monday as per <a href="https://downdetector.com/status/openai/">Down Detector</a>.
Price Action: Microsoft stock is down 0.33% at $417.40 premarket at last check Tuesday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42144915/china-unveils-global-ai-governance-committee-with-alibaba-cloud-founder-at-the-helm" target="_blank" rel="noreferrer noopener">China Unveils Global AI Governance Committee With Alibaba Cloud Founder At The Helm</a></li>
</ul>
Image: Shutterstock

News

Tech

MSFT

Microsoft Service Disruption Hits Outlook And Teams, Thousands Report Issues

WLDS

Wearable Devices shares are trading lower. The company announced it entered into a securities purchase agreement for the sale of 822,000 shares through a registered direct offering priced at $2.25 per unit.

BMO Capital analyst Andrew Strelzik maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Outperform and lowers the price target from $55 to $51.

Price Target

Analyst Ratings

PLAY

BMO Capital Maintains Outperform on Dave & Buster's Enter, Lowers Price Target to $51

Goldman Sachs analyst Kash Rangan maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral and raises the price target from $72 to $86.

Goldman Sachs Maintains Neutral on Zoom Video Comms, Raises Price Target to $86

<a href="https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan">https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan</a>
&nbsp;
<a href="https://www.aon.com/">Aon plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), a leading global professional services firm, today announced the signing of a definitive agreement to acquire the in-house insurance agency business of Mitsubishi Chemical Group (MCG) enhancing Aon's risk and health capability offering in Japan.
The in-house insurance agency operates as part of Dia Rix, an in-house business services provider to MCG. Aon will acquire the insurance agency business which provides corporate and personal lines insurance to MCG group companies and employees in Japan. The divestiture will allow MCG to divert resources and investment to its core business while leveraging the global risk management capabilities of Aon to strengthen its global governance.
Following the close of the transaction, the team will transition to Aon's brand and operating model, under the leadership of Tatsuya Yamamoto, head of Aon in Japan, bringing together a combined team of more than 400 colleagues.
Anne Corona, CEO for Aon in Asia Pacific said: "This acquisition reinforces our investment in Japan as an important market for Aon. The existing synergies we share with Dia Rix in terms of capability and culture will allow us to better serve MCG as well as strengthen broader capability and development opportunities for colleagues at the combined firm."
Tatsuya Yamamoto added: "The current changes in the non-life insurance environment in Japan will foster an environment in which global companies like the MCG can focus on their core business by divesting their in-house insurance agency operations, while at the same time supporting their operational efficiency strategies and leveraging a group of experts like Aon to provide an opportunity for more sophisticated global risk management. We are well situated to take this business forward building on our existing capabilities and growth momentum and continue to provide optimal solutions for all our clients in Japan."
The firms will continue to operate independently until the transaction is completed, which is expected in early 2025.

Global

Aon To Acquire In-House Insurance Agency Of Mitsubishi Chemical Group In Japan; No Financial Terms Disclosed

Looking into the current session, Hercules Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) shares are trading at $18.86, after a 0.37% decrease. Over the past month, the stock fell by 5.80%, but over the past year, it actually went up by 21.09%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_0.png" alt="Past Year Chart" />

<h3>How Does Hercules Capital P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Hercules Capital has a lower P/E than the aggregate P/E of 24.2 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

HTGC

Price Over Earnings Overview: Hercules Capital

Goldman Sachs analyst Ryan Nash maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and raises the price target from $59 to $67.

ZION

Goldman Sachs Maintains Neutral on Zions Bancorp, Raises Price Target to $67

Goldman Sachs analyst John Mackay maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Neutral and raises the price target from $45 to $55.

Goldman Sachs Maintains Neutral on Williams Companies, Raises Price Target to $55

Macro Economic Events

Econ #s

Economics

S&P/CS HPI Composite - 20 n.s.a. (MoM) For September -0.4% Vs -0.3% Prior

S&P/CS HPI Composite - 20 n.s.a. (YoY) For September 4.6% Vs 4.7% Est.; 5.2% Prior

President-elect Donald Trump dropped an economic bombshell Monday, announcing plans to slap hefty tariffs on key U.S. trade partners once he returns to the White House <a href="https://www.benzinga.com/topic/donald-trump">on Jan. 20. </a>
Trump pledged 25% tariffs on all Mexican and Canadian imports and an additional 10% levy on Chinese goods, which would remain in place until drugs, and in particular fentanyl, will stop entering the U.S.
&#8220;Thousands of people are pouring through Mexico and Canada, bringing crime and drugs at levels never seen before,&#8221; Trump wrote on Truth Social.
&#8220;On January 20th, as one of my many first executive orders, I will sign all necessary documents to charge Mexico and Canada a 25% tariff on ALL products coming into the United States. This tariff will remain in effect until such time as drugs, in particular Fentanyl, and all illegal aliens stop this Invasion of our country!&#8221;
<h3 class="wp-block-heading">Markets React: Peso And Loonie Hit Hard</h3>
Currency markets were the immediate shock absorber of the news. The Canadian dollar, tracked by the Invesco CurrencyShares Canadian Dollar Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXC#NYSE">FXC</a>), nosedived 0.8%, breaching the 1.41 level against the U.S. dollar — a low not seen since April 2020.
The Mexican peso didn't fare much better, sliding 0.9% to 20.50 against the greenback, while the Chinese yuan slumped 0.4% to a four-month low.
Robin Brooks, economist at the Brookings Institution, warned that this may only be the beginning. "The Mexican Peso is down 1.5% after tonight&#8217;s tariff news from the president-elect. To put this fall in perspective, the Mexican peso fell 10% in just a few days right after Trump's surprise win in 2016. So this fall is small and only the beginning of a sorely needed repricing."
The iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) fell 1.5% in premarket trading on Tuesday.
James Thorne, a market strategist at Wellington Altus, questioned the practicality of Trump's rhetoric. "Do you really think Mr. Trump will put a 25% tariff on Canadian Sour Crude Oil?" Thorne wrote. "Recall it's mixed with Sweet Shale oil and then refined. Constraint of US refining capacity. Think about that for 1 minute."
<h3 class="wp-block-heading">China In The Crosshairs: Fentanyl And Tariffs</h3>
Trump renewed his criticism of China, blaming the country for America's fentanyl epidemic.
&#8220;I have had many talks with China about the massive amounts of drugs, in particular Fentanyl, being sent into the United States—But to no avail," Trump said. 
He accused Chinese officials of failing to deliver on promises to crack down on drug dealers, stating, "Until such time as they stop, we will be charging China an additional 10% tariff, above any additional tariffs, on all of their many products coming into the United States of America."
The tariffs, according to Trump, would serve as a dual-purpose weapon: curbing illegal drug imports and bolstering his "America First" economic policy.
<h3 class="wp-block-heading">Bill Ackman: Trump Is Using Tariffs As Weapon</h3>
Prominent investor Bill Ackman chimed in on X (formerly Twitter), suggesting that Trump's tariffs are less about trade and more about leverage. 
"To be clear, according to Trump, the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S.," Ackman said. 
"In other words, Donald Trump is going to use tariffs as a weapon to achieve economic and political outcomes which are in the best interest of America, fulfilling his America First policy."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, according to Trump the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S. In other words, <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> is going to use tariffs as a weapon to achieve… <a href="https://t.co/61oQvCpW92">https://t.co/61oQvCpW92</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1861198845574815947?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Emerging Markets

Emerging Market ETFs

Currency ETFs

Politics

Forex

Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs 'As A Weapon'

USA House Price Index (MoM) For September 0.7% Vs 0.3% Est.; 0.4% Prior

Goldman Sachs analyst Ryan Nash maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Buy and raises the price target from $50 to $60.

Goldman Sachs Maintains Buy on Truist Finl, Raises Price Target to $60

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy&#xAE;, Ozempic&#xAE;, and Rybelsus&#xAE;), owned by Novo Nordisk&#xAE;; and tirzepatide (Zepbound&#xAE;, Mounjaro&#xAE;), owned by Eli Lilly&#x2122;. All five of those drug brands, with the exception of Rybelsus&#xAE;, are administered by injection, whereas Rybelsus&#xAE; is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and <a href="https://pr.report/4ja2">Wegovy&#xAE; was also approved by the FDA</a> in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of <a href="https://pr.report/4ja3">~$30 billion, compared to just $300 million in 2018</a>, an increase of 100x or 10,000%.

Biotech

General

LEXX

LEXXW

Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/24/11/42165679/nio-analyst-sees-tougher-path-to-profitability-downgrades-ev-maker-to-sell-what-you-need-to-know" rel="noreferrer noopener">premarket session on Tuesday.</a>
The Chinese EV manufacturer recently marked its 10th anniversary, with the company&#8217;s founder, chairman, and CEO, William Li, addressing employees through an internal letter.
In the message, Li emphasized the critical importance of the next two years for the company&#8217;s future, <a target="_blank" href="https://cnevpost.com/2024/11/25/nio-10th-anniversary-william-li-internal-letter/" rel="noreferrer noopener">reported</a> CnEV Post. Li outlined key objectives, including the launch of competitive new products and enhancing operational efficiency.
These efforts are aimed at doubling NIO&#8217;s sales in the coming year and achieving profitability by 2026, which he described as non-negotiable goals. Li urged the team to focus their full energy on meeting these targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more" rel="noreferrer noopener">J.M. Smucker Q2: Earnings Beat, 17% Sales Surge, FY25 EPS Outlook Boost &amp; More</a>
This week, Goldman Sachs analyst Tina Hou downgraded NIO from&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90, citing competitive pressures <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">and a difficult path to profitability ahead</a>.
The analyst notes NIO is unfavorably positioned heading into 2025 given the slow production ramp of&nbsp;Onvo and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv" rel="noreferrer noopener">limited new model pipeline.</a>
Recently, NIO guided deliveries of 72,000–75,000 units for the fourth quarter, or a 43.9% – <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">49.9% year-over-year increase.&nbsp;</a>
The company expects&nbsp;fourth-quarter revenue&nbsp;of $2.804 billion &#8211; $2.904 billion, representing 15.0% – 19.2% year-over-year growth.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 35% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Price Action: NIO shares are trading lower by 1.29% to $4.61 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Movers

Media

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With NIO Stock Today?

Goldman Sachs analyst Ryan Nash maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Neutral and raises the price target from $52 to $62.

Goldman Sachs Maintains Neutral on Synovus Finl, Raises Price Target to $62

Goldman Sachs analyst Ryan Nash maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $29 to $33.

Goldman Sachs Maintains Buy on Regions Finl, Raises Price Target to $33

Goldman Sachs analyst Gabriela Borges maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $19 to $21.

Comments

WisdomTree U.S. High Yield Corporate Bond Fund

News

Latest news for WisdomTree U.S. High Yield Corporate Bond Fund (BATS:QHY)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga